^
    2ms
    Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, John Rieth | Terminated --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2ms
    Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    3ms
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3ms
    EXAMINER: A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (clinicaltrials.gov)
    P4, N=247, Active, not recruiting, Exelixis | Trial completion date: Dec 2023 --> Jan 2035
    Trial completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    3ms
    Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=28, Terminated, John Rieth | Trial completion date: Dec 2026 --> Sep 2024 | Active, not recruiting --> Terminated; Study was terminated early due to changes in the treatment of melanoma
    Trial completion date • Trial termination
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    4ms
    Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, University of California, Irvine | N=20 --> 34 | Trial completion date: Dec 2024 --> May 2026
    Enrollment change • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    5ms
    ADVL1622: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (clinicaltrials.gov)
    P2, N=109, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2026
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • AXL (AXL Receptor Tyrosine Kinase)
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    7ms
    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Utah | Trial primary completion date: Apr 2025 --> May 2026
    Trial primary completion date
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    8ms
    Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, Irvine | Trial completion date: Feb 2025 --> Feb 2026
    Trial completion date
    |
    RAS wild-type
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Lonsurf (trifluridine/tipiracil)
    8ms
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    8ms
    IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov)
    P3, N=1000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • paclitaxel • sunitinib • Alecensa (alectinib) • Cotellic (cobimetinib) • Zejula (niraparib) • Xtandi (enzalutamide) • Cabometyx (cabozantinib tablet) • Rubraca (rucaparib) • pemetrexed • Cometriq (cabozantinib capsule) • emactuzumab (RG7155) • simlukafusp alfa (RG7461)
    8ms
    LITESPARK-011: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (clinicaltrials.gov)
    P3, N=708, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Welireg (belzutifan)